foxo4-dri for senescent cells — ≥99% Purity, COA Included Development of a novel senolytic
Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Figure 5 FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging FOXO4 DRI PEPTIDE 2MG 5MG 10MG VIAL UMBRELLA Labs FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv FOXO4 DRI Peptide Potential Interactions with Aged Cell Cultures
Pay in 4 interest-free payments of $6.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15





